Fremanezumab is a well-tolerated and effective preventive therapy in patients with migraine for whom two to four preventives have failed.
Researchers conducted a phase IIIb randomized controlled trial with fremanezumab, a calcitonin gene-related peptide (CGRP) monoclonal antibody, funded by the manufacturer. Patients with either episodic (n=329) or chronic migraine (n=509) who had failed two to four previous preventives (including beta-blockers, tricyclic antidepressants, valproate, topiramate, candesartan, flunarizine, and onabotulinumtoxinA) were randomized to placebo, to quarterly subcutaneous injections of 675 mg of fremanezumab (n=276) or to monthly subcutaneous injections of 225 mg (n=283) for 12 weeks.
Episodic and chronic migraineurs treated either with quarterly or monthly fremanezumab collectively had significantly fewer migraine days than placebo recipients: 3.1 and…
Reviewing Authors
DisclosuresConsultant/Advisory BoardAeon Biopharma; Allergan/Abbvie; CoolTech LLC; Dr Reddys; Eli Lilly and Company, Epalex; Lundbeck; Novartis; Pfizer; Praxis; Sanofi; Teva Pharmaceuticals and Tremeau; Gerson Lehrman Group; Guidepoint; Massachusetts Medical Society; Vector Metric; UptoDate
RoyaltiesOxford University Press; Wolters Kluwer
Grant/Research SupportCelgene
Leadership Positions in Professional SocietiesAmerican Headache Society (Immediate Past President)
OtherPatent on magnetic stimulation for headache assigned to eNeura without fee
DisclosuresConsultant/Advisory BoardAeon Biopharma; Allergan/Abbvie; CoolTech LLC; Dr Reddys; Eli Lilly and Company, Epalex; Lundbeck; Novartis; Pfizer; Praxis; Sanofi; Teva Pharmaceuticals and Tremeau; Gerson Lehrman Group; Guidepoint; Massachusetts Medical Society; Vector Metric; UptoDate
RoyaltiesOxford University Press; Wolters Kluwer
Grant/Research SupportCelgene
Leadership Positions in Professional SocietiesAmerican Headache Society (Immediate Past President)
OtherPatent on magnetic stimulation for headache assigned to eNeura without fee